DUBLIN, Aug. 07, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/nzj6mr/investigation) has announced the addition of the "Investigation Report on China's Adefovir Market, 2010-2019" report to their offering.

In March 2015, WHO issued Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection, indicating that 2 billion people around the world had or are having HBV infection and that about 240 million people are infected with chronic hepatitis B virus (HBV), among which 0.65 million die of hepatitis B-related diseases. Hepatitis B surface antigen (HBsAg ) rates among people aged below 60 has fallen from 9.75% a decade ago to 7.18% now. However, since China has a large population base, the number of people infected with chronic HBV is calculated to be over 90 million and the number of chronic hepatitis B (CHB) patients is 20 million. Hence, the severe status of diagnosis and treatment of CHB. So far, chronic and viral hepatitis B has become one of the major threats to human health and CHB has already become the ninth leading cause of death.

Nucleotide analog, the leading antiviral product for the treatment of CHB, has such main varieties as entecavir, adefovir dipivoxil, lamivudine, telbivudine, emtricitabine and tenofovir disoproxil in the clinic.

In 2002, GlaxoSmithKline (GSK) acquired the franchise rights to market adefovir dipivoxil, the anti-hepatitis B drug of Gilead Sciences, Inc. in mainland China, Japan, Korea and Taiwan under the trade name of Hepsera. In 2013, the global sales value of Hepsera was down by 23.81%. In 2005, adefovir dipivoxil made by GSK was first approved to enter China under the trade name of Hepsera.

Adefovir developed fast after entering China, with annual sales value rising from about CNY 10 million in 2005 to CNY 400 million in 2013 and CAGR reaching nearly 60% during the period of 2005-2014. GlaxoSmithKline (Tianjin) Co., Ltd, United Laboratories, Fujian Cosunter Pharmaceutical Co., Ltd and Chia Tai Tianqing Pharmaceutical Group Co., Ltd occupy the majority of the Chinese market, among of which GlaxoSmithKline (Tianjin) Co., Ltd had the largest market share of about 43% for sales value in 2014.

With the large amounts of hepatitis B patients in China, the market size of adefovir is expected to keep growing in the next few years.

Key Topics Covered:

1 Related Concepts of Adefovir

2 Market Profile of Adefovir in China

3 Survey on Sales Status of Adefovir in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Adefovir in China, 2010-2014

5 Survey on Dosage Forms of Adefovir in China, 2010-2014

6 Reference Price of Adefovir in Chinese Hospitals in 2014

7 Major Manufacturers of Adefovir in Chinese Market, 2010-2014

8 Market Outlook of Adefovir in China, 2015-2019

Companies Mentioned

- Chia Tai Tianqing Pharmaceutical Group Co., Ltd
- TIPR Pharmaceutical Responsible Co., Ltd
- United Laboratories
- Fujian Cosunter Pharmaceutical Co., Ltd
- GlaxoSmithKline (Tianjin) Co., Ltd

For more information visit http://www.researchandmarkets.com/research/nzj6mr/investigation

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets